Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiac metastasis from non-visceral sarcoma.
Wang WJ, Hsu CY, Chiou JF, Huang Y. Wang WJ, et al. Lancet Oncol. 2020 Jan;21(1):e66. doi: 10.1016/S1470-2045(19)30685-0. Lancet Oncol. 2020. PMID: 31908310 No abstract available.
Recent Advances in Metal-Based NanoEnhancers for Particle Therapy.
Chuang YC, Wu PH, Shen YA, Kuo CC, Wang WJ, Chen YC, Lee HL, Chiou JF. Chuang YC, et al. Among authors: wang wj. Nanomaterials (Basel). 2023 Mar 10;13(6):1011. doi: 10.3390/nano13061011. Nanomaterials (Basel). 2023. PMID: 36985905 Free PMC article. Review.
LC-MS/MS and EMIT measure the whole blood concentration of cyclosporine A: The two methods yield concordant results within the dynamic range of the latter, but the former shows broader application scenarios.
Zhang YY, Guo HL, Wang J, Wang WJ, Li Y, Chu CC, Wu CY, Huang J, Hu YH, Chen F. Zhang YY, et al. Among authors: wang wj. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 May 10;1240:124154. doi: 10.1016/j.jchromb.2024.124154. Online ahead of print. J Chromatogr B Analyt Technol Biomed Life Sci. 2024. PMID: 38749100
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.
2,035 results